@inbook{a._h._s._b_2022, place={Singapore}, title={Conductive Polymers for Cardiovascular Applications}, url={https://link.springer.com/chapter/10.1007/978-981-16-3667-7_12}, DOI={10.1007/978-981-16-3667-7_12}, booktitle={Nanoscale Engineering of Biomaterials: Properties and Applications}, publisher={Springer}, author={A., Arshad and H., Irfan and S., Iftikhar and B, Yameen}, editor={L.M., Pandey and A, HasanEditors}, year={2022} }
 @article{kanwal_naveed_arshad_arshad_firdous_faisal_yameen_2021, title={Reduction-Sensitive Dextran–Paclitaxel Polymer–Drug Conjugate: Synthesis, Self-Assembly into Nanoparticles, and In Vitro Anticancer Efficacy}, volume={32}, url={http://dx.doi.org/10.1021/acs.bioconjchem.1c00492}, DOI={10.1021/acs.bioconjchem.1c00492}, abstractNote={Delivery systems that can encapsulate a precise amount of drug and offer a spatiotemporally controlled drug release are being actively sought for safe yet effective cancer therapy. Compared to polymer nanoparticle (NP)-based delivery systems that rely on physical drug encapsulation, NPs derived from stimuli-sensitive covalent polymer-drug conjugates (PDCs) have emerged as promising alternatives offering precise control over drug dosage and spatiotemporal drug release. Herein, we report a reduction-sensitive PDC "Dex-SS-PTXL" synthesized by conjugating dextran and paclitaxel (PTXL) through a disulfide bond-bearing linker. The synthesized Dex-SS-PTXL PDC with a precise degree of substitution in terms of the percentage of repeat units of dextran covalently conjugated to PTXL (27 ± 0.5%) and the amount of drug carried by the PDC (39 ± 1.4 wt %) was found to self-assemble into spherical NPs with an average size of 110 ± 34 nm and a ζ-potential of -14.09 ± 8 mV. The reduction-sensitive Dex-SS-PTXL NPs were found to release PTXL exclusively in response to the reducing agent concentration reflective of the intracellular reducing environment of the tumor cells. Challenging BT-549 and MCF-7 cells with Dex-SS-PTXL NPs revealed significant cytotoxicity, while the IC50 values and the mode of action (mitotic arrest) of Dex-SS-PTXL NPs were found to be comparable to those of free PTXL, highlighting the active nature of the intracellularly released drug. The developed PDC with its unique ability to self-assemble into NPs and stimuli-responsive drug release can enhance the success of the NP-based drug delivery systems during clinical translation.}, number={12}, journal={Bioconjugate Chemistry}, publisher={American Chemical Society (ACS)}, author={Kanwal, Sidra and Naveed, Muhammad and Arshad, Ali and Arshad, Azka and Firdous, Farhat and Faisal, Amir and Yameen, Basit}, year={2021}, month={Dec}, pages={2516–2529} }